

I vaccini anti-SARS-CoV2 in fase 4 “post marketing”

descrizione della piattaforma	tipo di vaccino candidato	trials	sviluppatori
vaccino a RNA	BNT162 (3 LNP-mRNAs)	NCT04760132 EUCTR2021-0000412-28 EUCTR2021-0000412-28	Pfizer/BioNTech +Fosun Pharma
virus inattivato	SARS-CoV-2 vaccine (inattivato)	NCT04456595 NCT04508075 NCT04582344 NCT04617483 NCT04651790	Sinovac Research and Development Co., Ltd
vettore virale non replicante	ChAdOx1-S - (AZD1222) (Covishield)	ISRCTN89951424 NCT04516746 NCT04540393 NCT04536051 EUCTR2020-005226-28-DE	AstraZeneca + University of Oxford
vaccino a RNA	mRNA -1273	NCT04470427	Moderna + National Institute of Allergy and Infectious Diseases (NIAID)